307,337 Shares in Harrow, Inc. $HROW Bought by Luxor Capital Group LP

Luxor Capital Group LP purchased a new position in shares of Harrow, Inc. (NASDAQ:HROW) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 307,337 shares of the company’s stock, valued at approximately $14,807,000. Harrow makes up about 0.7% of Luxor Capital Group LP’s portfolio, making the stock its 20th biggest holding. Luxor Capital Group LP owned 0.83% of Harrow at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in HROW. The Manufacturers Life Insurance Company increased its stake in shares of Harrow by 2.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after purchasing an additional 341 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Harrow by 1.7% in the 3rd quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock valued at $1,422,000 after purchasing an additional 500 shares during the last quarter. Pale Fire Capital SE grew its holdings in Harrow by 6.8% during the second quarter. Pale Fire Capital SE now owns 8,683 shares of the company’s stock worth $265,000 after purchasing an additional 550 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Harrow by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after purchasing an additional 790 shares during the period. Finally, Franklin Resources Inc. increased its position in Harrow by 4.0% during the third quarter. Franklin Resources Inc. now owns 26,529 shares of the company’s stock worth $1,278,000 after buying an additional 1,022 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Trading Up 2.4%

Shares of Harrow stock opened at $34.91 on Tuesday. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20. The firm has a 50-day moving average of $45.83 and a 200-day moving average of $43.64. Harrow, Inc. has a 52-week low of $20.85 and a 52-week high of $54.85. The stock has a market cap of $1.30 billion, a PE ratio of -205.34 and a beta of 0.05.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HROW. William Blair reaffirmed an “outperform” rating on shares of Harrow in a research report on Tuesday, March 3rd. HC Wainwright raised their price target on Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Cantor Fitzgerald decreased their price objective on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Harrow has a consensus rating of “Moderate Buy” and an average target price of $71.14.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.